Bank of Montreal
NKTR icon

Bank of Montreal’s Nektar Therapeutics NKTR Stock Holding History

Bank of Montreal’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-2,233
Closed -$350K – 3859
2013
Q3 		$350K Buy
+2,233
New +$413K ﹤0.01% 1978

Other funds holding NKTR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Bank of Montreal's NKTR Position: Q1 2025 in Review

Bank of Montreal sold out of Nektar Therapeutics (NKTR) in Q1 2025, closing a stake of 3,633 shares — an estimated $50.7K sold.

Bank of Montreal first reported a position in NKTR in Q2 2014 and held it in 41 quarters. The position peaked at $14.4M in Q3 2018. 154 funds tracked by Wall St. Rank hold NKTR as of Q1 2025.

  • Bank of Montreal reported no remaining Nektar Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Bank of Montreal sold 3,633 Nektar Therapeutics shares in Q1 2025, an estimated $50.7K.
  • Bank of Montreal first reported a position in Nektar Therapeutics in Q2 2014 and held it in 41 quarters.
  • Bank of Montreal's Nektar Therapeutics position peaked at $14.4M in Q3 2018.
  • 154 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2025.

Based on Bank of Montreal's 13F filing for Q1 2025, filed 13 May 2025.